BioCentury
ARTICLE | Clinical News

GWP42006: Phase I data

March 31, 2014 7:00 AM UTC

A double-blind, placebo-controlled, U.K. Phase I trial in 66 healthy volunteers showed that single and multiple doses of 25, 75, 200 and 400 mg oral GWP42006 were well tolerated with no serious advers...